1. Home
  2. AYTU vs TSBX Comparison

AYTU vs TSBX Comparison

Compare AYTU & TSBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • TSBX
  • Stock Information
  • Founded
  • AYTU N/A
  • TSBX 2015
  • Country
  • AYTU United States
  • TSBX United States
  • Employees
  • AYTU N/A
  • TSBX N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • TSBX
  • Sector
  • AYTU Health Care
  • TSBX
  • Exchange
  • AYTU Nasdaq
  • TSBX Nasdaq
  • Market Cap
  • AYTU 10.5M
  • TSBX 10.2M
  • IPO Year
  • AYTU N/A
  • TSBX 2023
  • Fundamental
  • Price
  • AYTU $1.72
  • TSBX $0.43
  • Analyst Decision
  • AYTU
  • TSBX Buy
  • Analyst Count
  • AYTU 0
  • TSBX 3
  • Target Price
  • AYTU N/A
  • TSBX $4.75
  • AVG Volume (30 Days)
  • AYTU 27.9K
  • TSBX 158.9K
  • Earning Date
  • AYTU 02-12-2025
  • TSBX 03-20-2025
  • Dividend Yield
  • AYTU N/A
  • TSBX N/A
  • EPS Growth
  • AYTU N/A
  • TSBX N/A
  • EPS
  • AYTU N/A
  • TSBX N/A
  • Revenue
  • AYTU $79,759,000.00
  • TSBX N/A
  • Revenue This Year
  • AYTU N/A
  • TSBX N/A
  • Revenue Next Year
  • AYTU N/A
  • TSBX N/A
  • P/E Ratio
  • AYTU N/A
  • TSBX N/A
  • Revenue Growth
  • AYTU N/A
  • TSBX N/A
  • 52 Week Low
  • AYTU $1.30
  • TSBX $0.40
  • 52 Week High
  • AYTU $3.45
  • TSBX $5.75
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 54.22
  • TSBX 39.13
  • Support Level
  • AYTU $1.68
  • TSBX $0.41
  • Resistance Level
  • AYTU $1.93
  • TSBX $0.62
  • Average True Range (ATR)
  • AYTU 0.12
  • TSBX 0.06
  • MACD
  • AYTU 0.00
  • TSBX -0.01
  • Stochastic Oscillator
  • AYTU 36.36
  • TSBX 8.96

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

About TSBX Turnstone Biologics Corp.

Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

Share on Social Networks: